Organon & Co. (NYSE:OGN) & Unicycive Therapeutics (NASDAQ:UNCY) Financial Contrast

Organon & Co. (NYSE:OGN) and Unicycive Therapeutics (NASDAQ:UNCY) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Organon & Co. and Unicycive Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2	5	0	0	1.71
Unicycive Therapeutics	1	1	5	0	2.57

Organon & Co. currently has a consensus target price of $11.40, suggesting a potential downside of 17.93%. Unicycive Therapeutics has a consensus target price of $18.25, suggesting a potential upside of 398.63%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Organon & Co..

Institutional and Insider Ownership

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Organon & Co. and Unicycive Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.49%	82.06%	6.03%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Earnings & Valuation

This table compares Organon & Co. and Unicycive Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22 billion	0.59	$187.00 million	$0.76	18.28
Unicycive Therapeutics	$680,000.00	149.90	-$26.56 million	($1.75)	-2.09

Organon & Co. has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Organon & Co. has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.

Summary

Organon & Co. beats Unicycive Therapeutics on 8 of the 14 factors compared between the two stocks.

About Organon & Co.

Organon & Co. is a global health care company focused on women’s health, biosimilars and established medicines. It develops and markets prescription medicines and other health products for patients and health care professionals. Its women’s health portfolio includes contraceptive and fertility products, while its biosimilars business offers biologic medicines in areas such as immunology and oncology. The company also sells established medicines across several therapeutic areas, including cardiovascular health, respiratory conditions and dermatology.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company’s primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis. Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.